Today The Wells Fargo & Company MN Has $117,000 Stake in Codexis, Inc. (CDXS)

Today The Wells Fargo & Company MN Has $117,000 Stake in Codexis, Inc. (CDXS)

Wells Fargo & Company MN increased its position in Codexis, Inc. (NASDAQ:CDXS) by 412.3% during the third quarter, Holdings Channel reports. The firm owned 26,279 shares of the company’s stock after buying an additional 21,149 shares during the period. Wells Fargo & Company MN owned about 0.06% of Codexis worth $117,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in shares of Codexis by 113.4% in the second quarter. Bank of New York Mellon Corp now owns 117,756 shares of the company’s stock worth $475,000 after buying an additional 62,575 shares during the period. California State Teachers Retirement System bought a new position in shares of Codexis during the second quarter worth about $283,000. Vanguard Group Inc. raised its position in shares of Codexis by 17.8% in the second quarter. Vanguard Group Inc. now owns 965,982 shares of the company’s stock worth $3,893,000 after buying an additional 145,963 shares during the period. BlackRock Investment Management LLC raised its position in shares of Codexis by 2,070.5% in the second quarter. BlackRock Investment Management LLC now owns 123,762 shares of the company’s stock worth $499,000 after buying an additional 118,060 shares during the period. Finally, BlackRock Fund Advisors raised its position in shares of Codexis by 957.9% in the second quarter. BlackRock Fund Advisors now owns 876,101 shares of the company’s stock worth $3,531,000 after buying an additional 793,284 shares during the period. 57.45% of the stock is currently owned by institutional investors and hedge funds.

Shares of Codexis, Inc. (NASDAQ:CDXS) traded down 2.86% during midday trading on Wednesday, reaching $5.10. 38,713 shares of the company’s stock traded hands. The stock has a 50 day moving average of $4.82 and a 200-day moving average of $4.50. Codexis, Inc. has a 52-week low of $2.93 and a 52-week high of $5.28. The stock’s market cap is $210.22 million.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Tuesday, November 8th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.23. The company earned $14.90 million during the quarter, compared to analysts’ expectations of $7.41 million. Codexis had a negative net margin of 10.60% and a negative return on equity of 5.25%. The business’s quarterly revenue was down 14.4% on a year-over-year basis. During the same period last year, the business earned $0.19 EPS. On average, equities research analysts expect that Codexis, Inc. will post ($0.20) EPS for the current year.

CDXS has been the topic of a number of research reports. Zacks Investment Research raised shares of Codexis from a “hold” rating to a “strong-buy” rating and set a $5.25 target price on the stock in a research report on Tuesday, October 11th. Ladenburg Thalmann raised shares of Codexis from a “neutral” rating to a “buy” rating and set a $6.25 target price on the stock in a research report on Wednesday, January 4th.

In related news, Director Patrick Y. Yang acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, November 15th. The stock was bought at an average price of $4.83 per share, with a total value of $48,300.00. Following the acquisition, the director now owns 320,340 shares in the company, valued at approximately $1,547,242.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.30% of the stock is owned by company insiders.

Codexis Company Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).

Related posts

Leave a Comment